AstraZeneca PLC (AZN) Quick Ratio (Acid-Test): 0.72
Is AstraZeneca PLC’s quick ratio (acid-test) high or low?
AstraZeneca PLC's quick ratio (acid-test) of 0.72 is in line with its 5-year average of 0.72, around the middle of its 5-year range (0.64–0.76).
As of Friday, June 12, 2026. 1.37% below its 12-month average of 0.73.
AZN Quick Ratio (Acid-Test) Chart
AZN Average Quick Ratio (Acid-Test) Chart
AZN Current vs Average Quick Ratio (Acid-Test) Chart
AZN Quick Ratio (Acid-Test) Metrics
QUICK RATIO (ACID-TEST)
0.72
QUICK RATIO (ACID-TEST) AVG TTM
0.73
QUICK RATIO (ACID-TEST) AVG 3Y
0.70
QUICK RATIO (ACID-TEST) AVG 5Y
0.72
QUICK RATIO (ACID-TEST) AVG 10Y
0.73
QUICK RATIO (ACID-TEST) AVG 15Y
0.88
QUICK RATIO (ACID-TEST) AVG 20Y
0.98
CURRENT VS TTM AVG
-1.37%
CURRENT VS 3Y AVG
+3.60%
CURRENT VS 5Y AVG
+0.47%
CURRENT VS 10Y AVG
-1.37%
CURRENT VS 15Y AVG
-17.83%
CURRENT VS 20Y AVG
-26.46%
AZN Competitors' Quick Ratio (Acid-Test)
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| AstraZeneca PLC (AZN) | $282.69B | 0.72 | 0.73 | 0.70 | 0.72 |
| Merck & Co., Inc. (MRK) | $298.29B | 1.30 | 1.23 | 1.17 | 1.09 |
| UnitedHealth Group Incorporated (UNH) | $368.30B | 0.79 | 0.81 | 0.80 | 0.79 |
| Amgen Inc. (AMGN) | $191.09B | 0.90 | 0.93 | 1.02 | 1.14 |
| Thermo Fisher Scientific Inc. (TMO) | $176.77B | 1.53 | 1.41 | 1.34 | 1.37 |
| AbbVie Inc. (ABBV) | $397.12B | 0.56 | 0.56 | 0.68 | 0.69 |
| Gilead Sciences, Inc. (GILD) | $156.28B | 1.31 | 1.38 | 1.29 | 1.26 |
| Abbott Laboratories (ABT) | $156.15B | 1.18 | 1.21 | 1.20 | 1.26 |
| Pfizer Inc. (PFE) | $149.18B | 0.87 | 0.90 | 0.87 | 0.95 |
| Intuitive Surgical, Inc. (ISRG) | $146.23B | 3.96 | 3.59 | 3.74 | 4.30 |
Liquidity Comparison
Quick Ratio
0.72
Excludes inventory
Current Ratio
0.94
Includes inventory
AstraZeneca PLC Quick Ratio (Acid-Test) Formula & Definition
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
AstraZeneca PLC Quick Ratio (Acid-Test) FAQ
- What is the quick ratio (acid-test) for AstraZeneca PLC (AZN)?
- The quick ratio (acid-test) for AZN stock is 0.72.
- Is AstraZeneca PLC's quick ratio (acid-test) high or low?
- AstraZeneca PLC's quick ratio (acid-test) of 0.72 is in line with its 5-year average of 0.72, around the middle of its 5-year range (0.64–0.76).
- What is the TTM average quick ratio (acid-test) for AstraZeneca PLC (AZN)?
- The TTM average quick ratio (acid-test) for AZN stock is 0.73.
- What is the 3Y average quick ratio (acid-test) for AstraZeneca PLC (AZN)?
- The 3Y average quick ratio (acid-test) for AZN stock is 0.70.
- What is the 5Y average quick ratio (acid-test) for AstraZeneca PLC (AZN)?
- The 5Y average quick ratio (acid-test) for AZN stock is 0.72.
- What is the 10Y average quick ratio (acid-test) for AstraZeneca PLC (AZN)?
- The 10Y average quick ratio (acid-test) for AZN stock is 0.73.
- What is the 15Y average quick ratio (acid-test) for AstraZeneca PLC (AZN)?
- The 15Y average quick ratio (acid-test) for AZN stock is 0.88.
- What is the 20Y average quick ratio (acid-test) for AstraZeneca PLC (AZN)?
- The 20Y average quick ratio (acid-test) for AZN stock is 0.98.
AstraZeneca PLC Quick Ratio (Acid-Test) History
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2025-12-31 | 0.72 |
| 2024-12-31 | 0.74 |
| 2023-12-31 | 0.64 |
| 2022-12-31 | 0.68 |
| 2021-12-31 | 0.76 |
| 2020-12-31 | 0.76 |
| 2019-12-31 | 0.68 |
| 2018-12-31 | 0.78 |
| 2017-12-31 | 0.62 |
| 2016-12-31 | 0.72 |
| 2015-12-31 | 0.93 |
| 2014-12-31 | 0.85 |
| 2013-12-31 | 1.15 |
| 2012-12-31 | 1.22 |
| 2011-12-31 | 1.37 |
| 2010-12-31 | 1.40 |
| 2009-12-31 | 1.25 |
| 2008-12-31 | 1.06 |
| 2007-12-31 | 0.99 |
| 2006-12-31 | 1.55 |
| 2005-12-31 | 1.69 |
| 2004-12-31 | 1.70 |
| 2003-12-31 | 1.29 |
| 2002-12-31 | 1.16 |
| 2001-12-31 | 1.23 |
| 2000-12-31 | 1.22 |
| 1999-12-31 | 1.11 |
| 1998-12-31 | 0.94 |
| 1997-12-31 | 1.14 |
| 1996-12-31 | 1.26 |
Related Metrics
About AstraZeneca PLC
AstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization. The company's extensive portfolio of treatments, including prominent examples like Tagrisso, Farxiga, and Symbicort, addresses critical areas such as cardiovascular, renal, metabolic, and oncological conditions. Furthermore, it provides essential solutions for COVID-19 and various rare diseases, with products like Vaxzevria and Soliris. AstraZeneca engages with primary and specialty care physicians worldwide, facilitating distribution through a robust network of representatives and local offices across the United Kingdom, continental Europe, the Americas, Asia, Africa, and Australasia. The firm actively drives innovation through strategic collaborations, partnering with entities such as Neurimmune AG for the development and commercialization of NI006, BenevolentAI for systemic lupus erythematosus drug discovery, Lunit for AI-powered digital pathology risk assessment in NSCLC, and Absci Corporation for AI-driven oncology target identification. Founded in 1992, the company was initially known as Zeneca Group PLC, subsequently rebranding to AstraZeneca PLC in April 1999, and maintains its headquarters in Cambridge, United Kingdom.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Pascal Claude Roland Soriot